Dendreon Corporation (NASDAQ:DNDN) announced today the presentation of two PROVENGE® (sipuleucel-T) abstracts from the Phase II STAND study and the PROCEED registry, and one abstract highlighting data from the ongoing Phase II study of DN24-02, an investigational active cellular immunotherapy for patients with surgically resected HER2+ urothelial cancer.
Help employers find you! Check out all the jobs and post your resume.
